SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

UPST is trending downwards as investors react to concerns about the company's loan portfolio and broader macroeconomic uncertainty, despite some community members citing the potential for a short squeeze. Discussions center on the impact of potential government shutdowns and future interest rate cuts. Some believe UPST is undervalued, while others express concerns about the company's business model and its ability to compete in the AI lending space.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors react to recent news regarding the company's Q3 earnings beat and maintained guidance, with the community weighing in on the potential impacts. A new AI robotics spinoff, Mind Robotics, is also generating buzz, with some comparing Rivian to Tesla. Community members are actively discussing Rivian's progress toward profitability and the upcoming R2 vehicle launch.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members point to signs of accumulation and a strong base forming, suggesting potential for a significant move. The focus remains on organic growth and long-term vision, with many believing that the current quiet phase precedes a notable breakout. Discussions revolve around whale activity and anticipation for a catalyst or update.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending due to positive earnings news, sparking excitement among retail traders who see potential for a short squeeze. Community discussions focus on the high short interest and comparison to past squeeze events like Carvana. With a turnaround story and notable institutional investment, the stock is garnering attention as a potential high-reward play.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors discuss its potential, following positive earnings and future growth prospects, including the acquisition of Marigold. The community is weighing the company's valuation, partnership with OpenAI, and potential for a short squeeze given the high short interest. Discussions also involve speculation around analyst target hikes and the impact of seasonal trends on small-cap stocks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors weigh its potential in the AI server market against concerns about profitability and management. Community members are actively debating whether the stock is undervalued and buying the dip, while others express frustration with the company's consistent earnings volatility. The conversation also considers the broader AI sector and SMCI's competitive positioning.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending due to an FDA Complete Response Letter (CRL) for its drug troriluzole, intended to treat Spinocerebellar Ataxia, leading to a significant drop in share price. The community is discussing the implications of the CRL, the path forward involving a meeting with the FDA, and the potential impact on Biohaven's pipeline and cash burn. Despite the setback, some investors remain hopeful due to the company's obesity program and upcoming data release, viewing the dip as a buying opportunity.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending due to a mixed Q3 earnings report, including lowered sales guidance, triggering a stock dip despite some analysts remaining bullish. Community sentiment is divided, with some investors expressing disappointment and exiting positions, while others view the dip as a buying opportunity, citing the company's growth potential and expansion plans. Broader market concerns about consumer spending and the performance of other restaurant chains like Chipotle are also influencing the stock's movement.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

ENVB is trending due to community discussion around its low float and potential for a squeeze, amplified by a recent reverse stock split. Some traders are expressing optimism for a potential surge, while others cite concerns about dilution following an increase in authorized shares. Chatter also mentions the company's intellectual property and potential legal battles.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Recent earnings and growth metrics have $UBER trending, though some investors are wary after an initial dip despite strong results; community members are actively debating whether the company is undervalued given its buyback program and long-term prospects. Discussions also highlight Uber's strategic positioning in the autonomous vehicle space and its potential impact on the broader market, though some express concern about profitability and competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks are a hot-button topic for retail investors on Stocktwits, where over&nbsp;four million users track these companies, hoping to spot the next big therapeutic breakthrough.Two names currently trending in the space are Mainz Biomed, a molecular genetics cancer diagnostic company based in Germany, and Aurinia Pharmaceuticals Inc., a Canadian biopharmaceutical firm focused on autoimmune disease treatments.Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.&nbsp;However, Aurinia maintains nearly three times the following of Mainz on the platform.&nbsp;A recent Stocktwits poll of over 1,100 respondents found that 53% believe Mainz offers more upside, compared to 34% favoring Aurinia.<figure class="image"><img style="aspect-ratio:1294/736;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MYNZ_vs_AUPH_poll_as_of_March_6_43ea585c2e.png" alt="MYNZ vs AUPH poll as of March 6.png" width="1294" height="736"><figcaption>MYNZ vs AUPH poll as of March 6. | source: Stocktwits</figcaption></figure>Maxim Group recently initiated coverage on Mainz with a ‘Buy’ rating and a $14 price target, highlighting its role in the $4 billion colorectal cancer screening market.&nbsp;The firm is optimistic about Mainz’s next-generation test, which uses mRNA biomarkers to improve the detection of pre-cancerous adenomas and potentially enhance colorectal cancer prevention.&nbsp;Mainz is conducting a clinical study on this test, with data expected in the second half of 2025, and plans to finalize protocols for a pivotal U.S. study in 2026.In October, Mainz reported fiscal first-half loss per share had narrowed to $0.48 from $1 a year earlier, with revenue rising to $520,773 from $499,049.&nbsp;The company’s cash and cash equivalents stood at $977,764.Retail traders on Stocktwits have pointed to increasing institutional investment in Mainz, with funds such as Artisan Mid Cap Fund reportedly raising their stakes.&nbsp;<stembedurl>https://stocktwits.com/CarterWood/message/607119518</stembedurl>Some traders speculate that Mainz could see significant catalysts, including an upcoming product launch, a potential partnership, accelerated clinical progress, or an FDA resubmission with fast-track approval.<stembedurl>https://stocktwits.com/FosterD_Nightfall/message/607091090</stembedurl>Aurinia, in contrast, has gained attention for its development of AUR200, a therapy targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The company believes this could become a best-in-class treatment for autoimmune diseases.&nbsp;It has already commercialized Lupkynis, the first FDA-approved oral therapy for adult patients with active lupus nephritis.In its latest financial report, Aurinia posted fourth-quarter earnings of $0.01 per diluted share, a sharp turnaround from a $0.19 loss a year earlier and better than analysts’ projected $0.02 per-share loss.&nbsp;Revenue for the quarter rose to $59.9 million from $45.1 million a year earlier but fell slightly below Wall Street estimates of $60.1 million.&nbsp;For 2025, Aurinia forecasts revenue between $250 million and $260 million, trailing the $274.4 million expected by analysts.Last year, Aurinia said it would <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-surges-on-insider-buying/cJa2dg8Rin">strengthen</a> its financial position by cutting nearly half its staff to save over $40 million annually.&nbsp;The company also made leadership changes, including CEO Peter Greenleaf’s conditional resignation as a director.&nbsp;As of Dec. 31, 2024, Aurinia held cash, cash equivalents, and investments totaling $358.5 million, up slightly from $350.7 million a year earlier.According to Koyfin data, short interest in Aurinia stood at 7%, compared to 5.1% for Mainz.&nbsp;Over the past year, Aurinia shares have gained more than 44%, though they are down over 9% year-to-date.&nbsp;Mainz, meanwhile, has fallen more than 86% in the past 12 months but has rebounded over 25% since the start of this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%. 

Equity

Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Mainz Biomed to organize HALLO DOC! event

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ( Mainz Biomed or the Company ), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ( Mainz Biomed or the Company ), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed presents ColoAlert at UDH Congress 2024

Mainz Biomed Presents ColoAlert  at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ( Mainz Biomed or the Company ), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed price target lowered by $2 at H.C. Wainwright, here's why

Mainz Biomed partners with Trusted Health Advisors

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaborationMainz Biomed's Pivotal FDA PMA clinical...

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

Mainz Biomed N.V.

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.39
Prev Close	$1.47
Open	$1.45
Dividend Yield	0.00%
50-Day Moving Average	$1.59
Beta	0.88
Avg. Volume	480,863.65
PE Ratio	-0.02

52-Week High	$14.39
52-Week Low	$1.28
Market Capitalization	$7.52M
EPS (Annual)	-$22.36
Price to Book	4.34
Revenue Per Employee	$34,384.27
Enterprise Value/EBITDA	N/A

MYNZ
Mainz Biomed B.V.

Feed

News

Sentiment

Fundamentals

Info

Latest MYNZ News

MYNZMainz Biomed B.V.